European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

PANcreatic CAncer Initial Detection via liquid biopsy

Descripción del proyecto

DE EN ES FR IT PL

Un análisis de sangre para diagnosticar el cáncer de páncreas

Los tumores liberan pequeñas cantidades de células o material celular en la circulación sanguínea. Esta es la base del potencial diagnóstico de las biopsias líquidas que, sin embargo, a menudo presentan el inconveniente de una baja sensibilidad o especificidad. El equipo del proyecto PANCAID, financiado con fondos europeos, trabaja para crear una prueba diagnóstica para el cáncer de páncreas, una de las principales causas de muerte relacionadas con el cáncer en todo el mundo. La prueba combinará múltiples biomarcadores e inteligencia artificial para el análisis con el fin de obtener una gran precisión y sensibilidad. Dado el pésimo pronóstico del cáncer de páncreas, se espera que la prueba de PANCAID ayude a su detección precoz para mejorar el tratamiento y el desenlace clínico de esta afección.

Objetivo

Pancreatic cancer (PDAC) is usually detected at late stages and most patients die within one year after diagnosis. In PANCAID we will therefore develop a blood test for early detection of PDAC. Despite tremendous technological advances in Liquid Biopsy Diagnostics (LBx), this goal is very ambitious because small tumors release only minute amounts of cells or cellular products (e.g. DNA, RNA, protein, metabolites) into the circulation. Thus, tests with a high sensitivity are required but increases in sensitivity are usually achieved on the expenses of reduced specificity which can lead to significant overdiagnosis leading to unnecessary stress for the individuals with a false-positive blood test and high costs for the health system. In PANCAID, we will therefore establish a blood test with high accuracy by analyzing large cohorts of patients with PDAC and its precursor lesions, individuals at risk to develop PDAC and appropriate age-matched control groups (healthy and non-cancer diseases frequent in the targeted population).
Ambitious objectives of PANCAID include (1) establishment of a unique resource of blood samples of early PDAC and risk groups (WP1); (2) Establishment of a breakthrough blood test for early diagnosis of PDAC (WP2); (3) Identification of the best composite biomarker panel by integrating multimodal features in an AI-assisted computational analysis; (4) Analysis of the socio-economic impact of early PDAC diagnosis (WP4); and (5) Definition of the ethics parameters relevant to early PDAC detection (WP5). A robust multi-biomarker panel will be determined during the training period (year 1-3) and subsequently validated on bio-banked blood samples (year 4-5). Depending on the outcome of this comprehensive analysis, PANCAID will provide the design of a future prospective study for validation of the developed composite blood test in an international multi-center setting required to introduce LBx into screening programs for high-risk individuals. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening’.

Ámbito científico

Palabras clave

Programa(s)

Tema(s)

Convocatoria de propuestas

HORIZON-MISS-2021-CANCER-02

Consulte otros proyectos de esta convocatoria

Régimen de financiación

HORIZON-RIA - HORIZON Research and Innovation Actions

Coordinador

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Aportación neta de la UEn
€ 2 114 223,75
Dirección
Martinistrasse 52
20251 Hamburg
Alemania

Ver en el mapa
Región
Hamburg Hamburg Hamburg
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 2 114 223,75

Participantes (18)

Socios (1)

Compartir esta página

Descargar

Última actualización: 30 Diciembre 2022

Mi folleto

Permalink: https://cordis.europa.eu/project/id/101096309/es

European Union, 2024